NCT04779892View on ClinicalTrials.gov

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Infliximab

100mg/vial

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY

NCT04779892 - The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety | Biotech Hunter | Biotech Hunter